| Literature DB >> 33330021 |
Yanxiong Shao1,2,3, Yuhan Song1,2,3, Siming Xu1,2,3, Siyi Li2,3,4, Haiwen Zhou1,2,3.
Abstract
BACKGROUND: Circular RNAs (circRNAs) are involved in the pathogenesis of several diseases. Among oral maxillofacial cancers, oral squamous cell carcinoma (OSCC) has the highest incidence. However, the role of circRNAs in OSCC is still not clear. The aim of our study was to evaluate the circRNA expression profile in OSCC and explore further the potential role of circRNAs in the pathogenesis of OSCC.Entities:
Keywords: circRNA; non-coding RNA; oral squamous cell carcinoma; pathogenesis; sequencing
Year: 2020 PMID: 33330021 PMCID: PMC7729060 DOI: 10.3389/fonc.2020.533616
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Identification of DE circRNAs in OSCC. (A) The characteristics of statistically significantly DE circRNAs with heatmap. (B) The characteristics of statistically significantly DE circRNAs with volcano plots. (C) The number of statistically significantly DE circRNAs. (D) The length of statistically significantly DE circRNAs. (E) The chromosomal localization of statistically significantly DE circRNAs. (F) The category of statistically significantly DE circRNAs.
Figure 2Eight out of 10 circRNAs showed the same directions and statistical significance as the expression changes of the circRNA sequencing, using PCR (*P < 0.05). (A–J) Expression of hsa_circ_0000857, hsa_circ_0001470, hsa_circ_0001766, hsa_circ_0004390, hsa_circ_0005050, hsa_circ_0006151, hsa_circ_0008603, hsa_circ_0032822, hsa_circ_0104368, hsa_circSENP2 in OSCC tissues and normal oral mucosal tissues.
Biological features of validated circular RNAs (circRNAs).
| CircRNA ID | GeneName | CircBase ID | Relative levels | P value | Category | Length |
|---|---|---|---|---|---|---|
| chr2:61712903-61717911- | XPO1 | has_circ_0005050 | 3.921 | 0.031 | Exonic | 621 |
| chr7:148716084-148718239- | PDI4 | hashsa_circ_0001766 | 4.373 | 0.002 | Exonic | 387 |
Figure 3(A–C) The top annotation cluster terms of upregulated circRNAs. (D–F) The top annotation cluster terms of downregulated circRNAs.
Biological processes of validated circRNAs.
| circRNA ID | GO ID | GO terms |
|---|---|---|
| hsa_circ_0005050 | GO:1901363; | Heterocyclic compound binding; |
| hsa_circ_0001766 | GO:1901363; | Heterocyclic compound binding; |
Figure 4Transcriptional misregulation in cancer (hsa05202), Rap1 signaling pathway (hsa04015), and pathways in cancer (hsa05200).
Figure 5miR-877-3p inhibitor reversed the inhibitory role of si-circ0001766 on expression of VEGFA in SCC9 and SCC25 cell lines. (A, B) circ0001766 and VEGFA were upregulated in SCC9 and SCC25. miR-877-3p was downregulated in SCC25. (C–F) Identification of the effects of si-circ0001766 and miR-877-3p on VEGFA in SCC9 and SCC25, using PCR and western blotting. * vs Ctrl p < 0.05; ** vs Ctrl p < 0.01; *** vs Ctrl p < 0.001; ### vs si-circ0001766 p < 0.001; && vs miR-877-3p inhibitor p < 0.001; &&& vs miR-877-3p inhibitor p < 0.001.
Figure 6miR-877-3p inhibitor reversed the inhibitory role of si-circ0001766 on expression of cell proliferation in SCC9 and SCC25 cell lines. (A, B) CCK assays revealed the effects of circ0001766 and miR-877-3p on cell proliferation in SCC25 and SCC25 cell lines. (C, D) Colony formation assay was used to evaluate cell viability after knocking down of circ0001766 and/or miR-877-3p. * vs Ctrl p < 0.05; ** vs Ctrl p < 0.01; *** vs Ctrl p < 0.001; ## vs si-circ0001766 p < 0.01; ### vs si-circ0001766 p < 0.001; && vs miR-877-3p inhibitor p < 0.001; &&& vs miR-877-3p inhibitor p < 0.001.